

Aquacel® Ag+ Extra™ with Antibiofilm MTS™: Delivering better outcomes at lower costs^{1,3*}

i Background



Venous leg ulcers (VLUs) affect ~1% of adults annually; up to 40% are non-healing, creating major clinical and economic burden.¹



Hard-to-heal VLUs are associated with pain, infection, reduced mobility, and significant health service utilisation.²



Aquacel® Ag+ Extra™ is a gelling fibre dressing with Antibiofilm More Than Silver™ Technology.³



Overview


The aim of the RCT and HEOR studies was to evaluate the effectiveness of Aquacel® Ag+ Extra™ with Antibiofilm MTS™ Technology vs DACC for hard-to-heal VLUs.^{1*}

A NICE LSA includes an HE analysis of infected LU management.^{4,5}



Results

Initiating treatment with Aquacel® Ag+ Extra™ with Antibiofilm MTS™ Technology:
In the multi-country RCT at 12 weeks, the analysis showed statistically **significant 35% increased** likelihood of complete wound closure.^{3†}



NICE findings:^{4,5}

- ✓ Silver dressings used up to 12 weeks.
- ✓ Silver agents enable faster, cost-effective healing.
- ✓ Aquacel® Ag+ Extra™ saves >£500 per patient vs other silvers.⁵

Using UK RCT data, over 24 weeks, the cost-effectiveness analysis showed:¹




+5% Improvement in health-related quality of life.¹



- Aquacel® Ag+ Extra™ with Antibiofilm MTS™
- Elemental silver (e.g. Acticoat)
- Silver salts & compounds (e.g. UrgoClean Ag, Biatain Ag)

DACC (Cutimed® Sorbact®) excluded: no sufficient evidence of healing efficacy⁵



>23% reduction in cost of care, driven by fewer clinician visits and faster healing.¹



>£250 saved per patient, in total healthcare costs.¹

✓ Conclusion

Aquacel® Ag+ Extra™ with Antibiofilm MTS™ is the dominant treatment strategy: better outcomes at lower costs.¹

EU and US HE evidence shows improved healing lowers economic burden by reducing prolonged treatment.⁶⁻¹¹



Scan to read full article

* versus Cutimed® Sorbact® for hard-to-heal VLUs⁵ and for infected leg ulcers.^{4,5} † RR, 1.35; 95% CI, 1.10-1.65; p=0.0031.³ § over 1-year time horizon.^{4,5} DACC, dialkylcarbamoyl chloride-coated; RCT, randomised controlled trial; HEOR, Health Economics and Outcomes Research; NICE, National Institute for Health and Care Excellence; LSA, Late Stage Assessment; HE, Health Economics; LU, Leg Ulcer.

References: 1. Guest, J. F. (2025). JWC. 34(10),824-234. 2. Raffetto, J. D., et al. (2020). Journal of clinical medicine. 10(1), 29. 3. Beraldo, S., et al. (2025). JWC. 34(3), 170-178. 4. Holmes et al. (2025). Second Addendum. NICE. 5. Holmes et al. (2025). External Assessment Group Report. NICE. 6. Meaume, S., et al. (2023). JWC. 32(10), 615-623. 7. Da Ros, R., et al. (2024). Diabetology. 5(2), 141-150. 8. Diaz-Herrera, M. A., et al. (2025). Int J Nurs Stud Adv. 8: 100313. 9. Phillips, C. J., et al. (2020). IntWound J. 17(4), 1074-1082. 10. Rice, J. B., et al. (2014). J Med Econ. 17(5): 347-356. 11. Augustin, M., et al. (2014). IntWound J. 11(3), 283-292.

Not all claims are supported in all regulatory geographies. Aquacel® Ag+ Extra™ trademark is the property of Convatec group companies. All other trademarks are the property of their respective owners. ©2026 Convatec Inc. ©AP-77256-GBL-ENG-v5, February 2026.